Share this article
Share this article
DAEJEON, South Korea, Feb. 1, 2021 /PRNewswire/ ILIAS Biologics, Inc. announced that its latest research in collaboration with researchers at The University of Texas Medical Brand at Galveston (UTMB) is published in the journal
Science Advances(Link: https://advances.sciencemag.org/content/7/4/eabd3865). The study showed successful results in preventing preterm birth and improving the fetus viability with ILB-202, ILIAS s anti-inflammatory exosomes developed through its EXPLOR® platform technology.
This study result is the second proof of concept that suggests significant anti-inflammatory effects of the same exosome (ILB202) from ILIAS Biologics, Inc. In April 2020, the researchers at the Korea Advanced Institute of Science and Technology (KAIST) and the ILIAS team published the same exosome s substantial efficacy in the septic mouse model in